Table 3. Visit Outcomes for All Completed Hybrid Visits in the Year 2020.
| Outcomes measures | Visits, No. (%) (N = 940) |
|---|---|
| Procedure visit | 25 (2.7) |
| Intravitreal injection | 15 (1.5) |
| Panretinal photocoagulation | 2 (0.2) |
| Laser retinopexy | 2 (0.2) |
| Photodynamic therapy | 1 (0.1) |
| Nd:YAG capsulotomy | 1 (0.1) |
| Selective laser trabeculoplasty | 4 (0.4) |
| Medication adjustment | 22 (2.3) |
| Addition of intraocular pressure–lowering agent | 19 (2.0) |
| Medical management of macular edema | 2 (0.2) |
| Restarted treatment for symptomatic idiopathic intracranial hypertension | 1 (0.1) |
| Nonurgent referral | 44 (4.7) |
| Optometry | |
| Refraction | 10 (1.1) |
| Low vision | 3 (0.3) |
| Comprehensive | |
| Cataract evaluation | 10 (1.1) |
| Nd:YAG capsulotomy evaluation | 3 (0.3) |
| Glaucoma evaluation | 10 (1.1) |
| Neuro-ophthalmology evaluation | 2 (0.2) |
| Cornea evaluation | 1 (0.1) |
| Oculoplastic | 1 (0.1) |
| Retina, new diabetic macular edema evaluation | 1 (0.1) |
| Medical genetics | 3 (0.3) |
| Urgent referral | 0 |
Abbreviation: Nd:YAG, Neodymium-doped Yttrium Aluminum Garnet laser.